Hyperphosphatemia has an important role in the development of secondary hyperparathyroidism and bone disease in patients with end-stage renal disease (ESRD). The most effective method of phosphate elimination lies with phosphate binders, the agent that more commonly used, calcium carbonate, is not an ideal binding agent. In this regard, calcium acetate has been reported to have more or at least a similar phosphate binding efficacy and less pronounced hypercalcemic effect. However, this subject is still a matter of controversy. This study was designed to compare the efficiency of these salts. Preparation of calcium acetate and comparison of the phosphate binding power and hypercalcemic effect of calcium acetate with that of calcium carbonate...
Treatment of hyperphosphatemia with sevelamer hydrochloride in hemodialysis patients: A comparison w...
Phosphate binder therapy for attainment of K/DOQI™ bone metabolism guidelines. Hyperphosphatemia in ...
Hyperphosphatemia is an inevitable consequence of end-stage chronic kidney disease and is present in...
Hyperphosphatemia has an important role in the development of secondary hyperparathyroidism and bone...
Background: Hyperphosphatemia is common in end-stage renal disease patients. Objective of this study...
CONTEXT: Hyperphosphatemia has an important role in the development of bone and mineral abnormalitie...
High levels of serum phosphorus both at baseline and during follow-up are associated with increased ...
High levels of serum phosphorus both at baseline and during follow-up are associated with increased ...
Abstract. In order to avoid aluminium toxicity, calcium-containing phosphate binders have been used ...
This study included fourty chronic renal failure patients aged 37-83 years (mean 51.3±7) on thrice w...
Calcium acetate is used as an oral phosphate binder to control hyperphosphatemia in patients with ch...
Treatment of hyperphosphatemia in patients with chronic kidney disease on maintenance hemodialysis H...
In order to avoid aluminium toxicity, calciumcontaining phosphate binders have been used increasingl...
Calcium acetate, an effective phosphorus binder in patients with renal failure. Calcium salts are in...
Treatment of hyperphosphatemia in hemodialysis patients: The Calcium Acetate Renagel Evaluation (CAR...
Treatment of hyperphosphatemia with sevelamer hydrochloride in hemodialysis patients: A comparison w...
Phosphate binder therapy for attainment of K/DOQI™ bone metabolism guidelines. Hyperphosphatemia in ...
Hyperphosphatemia is an inevitable consequence of end-stage chronic kidney disease and is present in...
Hyperphosphatemia has an important role in the development of secondary hyperparathyroidism and bone...
Background: Hyperphosphatemia is common in end-stage renal disease patients. Objective of this study...
CONTEXT: Hyperphosphatemia has an important role in the development of bone and mineral abnormalitie...
High levels of serum phosphorus both at baseline and during follow-up are associated with increased ...
High levels of serum phosphorus both at baseline and during follow-up are associated with increased ...
Abstract. In order to avoid aluminium toxicity, calcium-containing phosphate binders have been used ...
This study included fourty chronic renal failure patients aged 37-83 years (mean 51.3±7) on thrice w...
Calcium acetate is used as an oral phosphate binder to control hyperphosphatemia in patients with ch...
Treatment of hyperphosphatemia in patients with chronic kidney disease on maintenance hemodialysis H...
In order to avoid aluminium toxicity, calciumcontaining phosphate binders have been used increasingl...
Calcium acetate, an effective phosphorus binder in patients with renal failure. Calcium salts are in...
Treatment of hyperphosphatemia in hemodialysis patients: The Calcium Acetate Renagel Evaluation (CAR...
Treatment of hyperphosphatemia with sevelamer hydrochloride in hemodialysis patients: A comparison w...
Phosphate binder therapy for attainment of K/DOQI™ bone metabolism guidelines. Hyperphosphatemia in ...
Hyperphosphatemia is an inevitable consequence of end-stage chronic kidney disease and is present in...